OXLUMO® Infusion Therapy

OXLUMO® (lumasiran) is a small interfering RNA (siRNA) therapeutic indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients. This medication targets the hydroxyacid oxidase 1 (HAO1) gene to reduce production of oxalate and is administered as a subcutaneous injection once monthly, with maintenance doses every 3 months.